Introduction and objectives The airflow limitation of COPD results from small airway disease and emphysema. These phenotypes are likely to have independent genetic risk factors. It is not known if the heterogeneity of COPD accounts for the relatively weak association between pack-years smoked and forced expiratory volume in 1 s (FEV 1 ) seen within smoking populations, or bronchodilator response (BDR). This study aimed to assess the effect of these phenotypes on the association between smoking and FEV 1 and on BDR. Method The international COPD genetics network is a multi-centre study aimed at identifying genes that predispose to COPD, in which high resolution computed tomography (HRCT) was used to quantify components of the COPD phenotype: (i) emphysema detected by radiologists (RE), (ii) emphysema assessed as per cent lowattenuation area (%LAA) and (iii) airway wall thickness (AWT) for airways with an internal perimeter of 10 mm (Pi10), 20 mm (Pi20), and average per cent wall area (WA%). They were then assessed for their effect on the association between smoking and lung function (FEV 1 % predicted (FEV 1 %)), and on BDR. Results RE data were available for 1159 individuals, 745 had complete data for Pi10, Pi20, AWT% and %LAA. The association between packyears smoked and FEV 1 % was greater in those without (r¼À0.41), compared to those with, RE (r¼À0.12, p<0.001 for difference in effect). AWT and RE correlated with FEV 1 % but had different relationships with smoking; AWT was positively associated with packyears but there was no relationship between RE severity and pack-years smoked. RE, %LAA and AWT made independent contributions to FEV 1 %. Post-bronchodilator increase in FEV 1 was inversely associated with severity of RE (Abstract S113 Table 1), even after adjustment for pre-bronchodilator FEV 1 (p<0.01). BDR was also inversely associated with %LAA (p¼0.02, and p#0.05 adjusted for baseline FEV 1 ).
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Abstract S113 Background Previous studies have shown a reduction in cough response to inhaled citric acid after blocking NK1, NK2 and also NK3 receptors in guinea pigs. NK3 receptor may be more relevant to study the role of tachykinins in cough due to their greater specificity for its agonist neurokinin B. We studied a specific NK3 receptor antagonist Talnetant to determine the effect on the human cough reflex sensitivity to citric acid in healthy individuals. Oral codeine and placebo were included as comparators.
Methods Double-blind, randomised, placebo-controlled, 4-period cross-over study in non-smoking healthy adult volunteers. A total of 28 subjects (12M, 16F) with mean age of 33 years (SD 10.5, range 22e55) were studied. Each subject received A. matched placebos; B. Talnetant 200 mg; C.Talnetant 25 mg; D. Codeine 60 mg, in a double blind double dummy manner. Subjects were randomly assigned to one of four treatment sequences (ABCD, BCDA, DCAB, BDCA). Each study period was 24 h with citric-acid challenges performed at 2, 6, 10 and 24 h post dose and a 7 day washout period between treatments.
Results There was no significant difference in logC5 Citric acid between Talnetant 25 mgs, 200 mgs and placebo at any time point (see Abstract S114 Figure 1) . The 'positive' control codeine had a non-significant trend for improvement in logC5 compared to placebo (all confidence intervals contained unity). Talantent was adequately absorbed with sustained blood levels at time points designed to coincide with the cough challenges.
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